Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
Christian Taverna(Kantonsspital St. Gallen), Michele Ghielmini(Institute of Oncology Research), Corinne Rusterholz(Swiss Group For Clinical Cancer Research), Felicitas Hitz(Kantonsspital St. Gallen), Daniel Vorobiof(The Medical Oncology Centre of Rosebank), Thomas Pabst(University Hospital of Bern), Walter Mingrone(Kantonsschule Olten), Daniele Laszlò(Kantonsspital St. Gallen), Johann Raats(Kantonsspital St. Gallen), Giovanni Martinelli(University of Bologna), Auro del Giglio(Faculdade de Medicina do ABC), Andreas Lohri(Kantonsspital St. Gallen), Emanuele Zucca(Università della Svizzera italiana), Stéphanie Rondeau(Kantonsspital St. Gallen), Ingmar Heijnen(University Hospital of Basel), Christine Biaggi Rudolf(Kantonsspital St. Gallen), Anna Vanazzi(European Institute of Oncology), Lidija Čevreska(Kantonsspital St. Gallen), Daniel Rauch(Washington University in St. Louis)
Cited by 63
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications
|Photodiagnosis and Photodynamic Therapy|2005|910